المؤلفون: Bradley, JS, Broadhurst, H, Cheng, K, Mendez, M, Newell, P, Prchlik, M, Stone, GG, Talley, AK, Tawadrous, M, Wajsbrot, D, Yates, K, Zuzova, A, Gardner, A

المصدر: Pediatric Infectious Disease Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

مصطلحات موضوعية: pediatric patients, meropenem, phase 2, Ceftazidime-avibactam plus metronidazole, complicated intra-abdominal infection

URL الوصول: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a6a248a4a61bf15e074155de9a29fd13
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3759

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Melnick D; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Talley AK; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Gupta VK; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Critchley IA; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Eckburg PB; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Hamed KA; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Bhatt N; Spero Therapeutics, Inc. , Cambridge, Massachusetts, USA., Moore G; Moore Computing Services, Inc. , Little Rock, Arkansas, USA., Austin D; GlaxoSmithKline , London, UK., Rubino CM; Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA., Bhavnani SM; Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA., Ambrose PG; Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA.

المصدر: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Oct 18; Vol. 67 (10), pp. e0053523. Date of Electronic Publication: 2023 Sep 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE

مواضيع طبية MeSH: Bacteriuria*/drug therapy , Bacteriuria*/complications , Urinary Tract Infections*/microbiology, Humans ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacokinetics ; Ertapenem/therapeutic use

المؤلفون: Ganesan H; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Gupta VK; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Safir MC; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Bhavnani SM; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Talley AK; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Melnick D; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Rubino CM; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.

المصدر: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Jun 15; Vol. 67 (6), pp. e0145122. Date of Electronic Publication: 2023 May 16.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE

مواضيع طبية MeSH: Prodrugs*/therapeutic use , Urinary Tract Infections*/drug therapy , Pyelonephritis*/drug therapy, Humans ; Anti-Bacterial Agents ; Carbapenems/pharmacokinetics ; Monobactams ; Administration, Oral

المؤلفون: Patel G; Patel Kwan Consultancy, LLC, Madison, Wisconsin, USA., Gupta VK; Spero Therapeutics, Cambridge, Massachusetts, USA., Gasink L; Spero Therapeutics, Cambridge, Massachusetts, USA., Bajraktari F; Spero Therapeutics, Cambridge, Massachusetts, USA., Lei Y; Spero Therapeutics, Cambridge, Massachusetts, USA., Jain A; Spero Therapeutics, Cambridge, Massachusetts, USA., Srivastava P; Spero Therapeutics, Cambridge, Massachusetts, USA., Talley AK; Spero Therapeutics, Cambridge, Massachusetts, USA.

المصدر: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Apr 18; Vol. 67 (4), pp. e0149522. Date of Electronic Publication: 2023 Mar 21.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE

مواضيع طبية MeSH: Antacids*/pharmacology , Anti-Ulcer Agents*, Adult ; Humans ; Administration, Oral ; Aluminum Hydroxide/pharmacology ; Cross-Over Studies ; Drug Interactions ; Magnesium Hydroxide/pharmacology ; Omeprazole/pharmacology ; Proton Pump Inhibitors/pharmacology ; Simethicone

المؤلفون: Gupta VK; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Patel G; Patel Kwan Consultancy LLC, Madison, Wisconsin, USA., Gasink L; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Bajraktari F; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Lei Y; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Jain A; Biogen, Cambridge, Massachusetts, USA., Srivastava P; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Talley AK; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA.

المصدر: Clinical and translational science [Clin Transl Sci] 2022 Jul; Vol. 15 (7), pp. 1654-1663. Date of Electronic Publication: 2022 Apr 28.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

مواضيع طبية MeSH: Therapeutic Equivalency*, Administration, Oral ; Adult ; Carbapenems ; Healthy Volunteers ; Humans ; Tablets

المؤلفون: Patel G; Patel Kwan Consultancy, LLC, Madison, Wisconsin, USA., Rodvold KA; University of Illinois, Chicago, Illinois, USA., Gupta VK; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Bruss J; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Gasink L; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Bajraktari F; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Lei Y; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Jain A; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Srivastava P; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA., Talley AK; Spero Therapeutics, Inc., Cambridge, Massachusetts, USA.

المصدر: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 May 17; Vol. 66 (5), pp. e0240721. Date of Electronic Publication: 2022 Apr 14.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE

مواضيع طبية MeSH: Kidney Failure, Chronic*/chemically induced , Kidney Failure, Chronic*/drug therapy , Renal Insufficiency*/drug therapy, Area Under Curve ; Carbapenems/therapeutic use ; Humans ; Monobactams/therapeutic use

المؤلفون: Eckburg PB; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Muir L; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Critchley IA; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Walpole S; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Kwak H; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Phelan AM; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Moore G; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Jain A; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Keutzer T; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Dane A; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Melnick D; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.)., Talley AK; From Spero Therapeutics, Cambridge, MA (P.B.E., L.M., I.A.C., S.W., H.K., A.-M.P., A.J., T.K., D.M., A.K.T.); Moore Computing Services, Little Rock, AR (G.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.).

المصدر: The New England journal of medicine [N Engl J Med] 2022 Apr 07; Vol. 386 (14), pp. 1327-1338.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Anti-Bacterial Agents*/administration & dosage , Anti-Bacterial Agents*/adverse effects , Anti-Bacterial Agents*/therapeutic use , Carbapenems*/administration & dosage , Carbapenems*/adverse effects , Carbapenems*/therapeutic use , Pyelonephritis*/drug therapy , Urinary Tract Infections*/drug therapy , Urinary Tract Infections*/microbiology, Administration, Intravenous ; Administration, Oral ; Adult ; Double-Blind Method ; Drug Resistance, Multiple, Bacterial ; Ertapenem/administration & dosage ; Ertapenem/adverse effects ; Ertapenem/therapeutic use ; Humans